海森生物搭建创新泛亚太商业化平台

Core Viewpoint - Haisen Biopharmaceutical Co., Ltd. has successfully established a comprehensive commercialization network across Southeast Asia, Australia, South Korea, Hong Kong, and Taiwan, completing 70 multi-country and regional Market Authorization Transfers (MAT) [1] Group 1: Strategic Expansion - Haisen Biopharmaceutical's Asia-Pacific strategic layout will significantly launch in June 2024, with multiple brand drug acquisitions completed in eight countries and regions [1] - The Asia-Pacific team will leverage capabilities in overseas product registration, market development, and compliance audits to build a Go-To-Market (GTM) system covering markets such as South Korea, Thailand, Malaysia, and Singapore [1] Group 2: Leadership Insights - The CEO of Haisen Biopharmaceutical emphasized the complexity of expanding into overseas markets and the challenges of establishing a commercial chain from scratch [1] - The Executive Vice President and Head of Asia-Pacific Commercial expressed that the company has successfully built a feasible commercialization full chain through deep local demand insights, aiming for comprehensive growth in overseas hospitals, clinics, and retail markets [1] Group 3: Market Engagement - The Asia-Pacific team has established a "demand insight-driven strategy" since its operational inception, exemplified by conducting numerous academic-driven satellite seminars in Thailand to enhance product awareness and brand influence [1]